Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology reported a wider quarterly loss and flagged liquidity risk in its Q3 results. For the quarter ended September 30, 2025, the company posted a net loss of $8.9 million as operating expenses rose, driven by research and development.
Cash was $10.9 million with working capital of approximately $1.76 million. Management stated there is substantial doubt about the company’s ability to continue as a going concern within one year without additional financing. Operating cash outflow was $11.8 million for the nine months, partially offset by financing inflows of $13.1 million, including at-the-market share sales and multiple private placements.
Quarterly operating expenses were $9.36 million (R&D $6.36 million; G&A $3.00 million). The warrant liability decreased to $1.75 million, contributing to other income. Shares outstanding were 34.45 million at quarter-end; authorized common shares were increased to 150 million earlier in the year. As of November 7, 2025, common shares outstanding were 37,032,307.
MAIA Biotechnology reported two upcoming scientific presentations and made the materials available as exhibits. The company prepared a THIO-104 Phase 3 trial-in-progress poster for immune checkpoint inhibitor–resistant advanced NSCLC, presented at SITC 2025 on November 7, 2025, and a THIO-101 Phase 2 trial-in-progress poster for the same setting, presented on November 10, 2025.
The THIO-104 poster is filed as Exhibit 99.1 and the THIO-101 poster as Exhibit 99.2, with both to be posted on the company’s website on their respective presentation dates. The company notes these materials contain forward-looking statements.
MAIA Biotechnology filed an 8-K noting two updates. The company announced a trial-in-progress poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, highlighting its pipeline activities. MAIA also reported enrolling five patients from Taiwan and Turkey in the expansion phase of its THIO-101 Phase 2 trial.
MAIA Biotechnology reported under Regulation FD that it presented a scientific poster titled “Presentation 1: A Phase 2 Study of Ateganosine (THIO; 6‑thio‑2’-deoxyguanosine) in combination with immune checkpoint inhibitor in patients with advanced NSCLC: THIO‑101 Trial.”
The poster was presented at the AACR‑NCI‑EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts on October 24, 2025 and was posted to the company’s website the same day. The poster is furnished as Exhibit 99.1. The company notes the poster contains forward‑looking statements.
MAIA Biotechnology furnished a Regulation FD Form 8-K to share a press release titled “MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer.” The company states this information is being provided for disclosure purposes.
The Item 7.01 materials are deemed “furnished” rather than “filed,” so they are not subject to Section 18 of the Exchange Act and are not incorporated by reference into other filings. Exhibits include the press release and scientific posters for the THIO-101 and THIO-104 trials, along with the cover page interactive data file.
MAIA Biotechnology entered a Securities Purchase Agreement for a private placement of 603,769 shares of common stock at $1.22 per share, together with warrants to purchase up to 603,769 shares, for expected gross proceeds of approximately $736,600. The warrants are exercisable at $1.52, begin six months after issuance, and expire three years from the issuance date.
The securities are being issued as restricted under Rule 144 with no registration rights and are offered in reliance on Section 4(a)(2) and/or Rule 506. Closing is expected on October 15, 2025, subject to customary closing conditions. The company plans to use net proceeds to fund the starting cost for Step 1 of Part C of its Phase II THIO‑101 trial and for working capital.
MAIA Biotechnology filed a current report describing a new treasury strategy that adds digital assets to how it manages its corporate funds. The company announced a plan to hold a portion of its treasury in a diversified portfolio focused on top-tier cryptocurrency assets, as detailed in an accompanying press release.
This move formally introduces exposure to cryptocurrencies at the corporate level, in addition to traditional cash and financial assets. The filing emphasizes that statements about this strategy and its future impact are forward-looking and subject to risks and uncertainties, including broader business, regulatory, and market factors affecting the company’s operations and product development.
MAIA Biotechnology reported a director stock-option grant disclosed on a Form 4. Stan V. Smith, a company director, received an award of 24,844 stock options on 10/02/2025 under the 2021 Equity Incentive Plan. The options have an exercise price of $1.80, vest 100% on the grant date, are exercisable immediately, and expire on 10/02/2035. The filing shows these shares are beneficially owned indirectly through The Stan V. Smith Trust Dated 1993, and the Form 4 was signed on 10/06/2025. The disclosure provides a clear record of insider compensation and ownership change but does not include company-wide share counts or percent ownership to measure dilution impact.
MAIA Biotechnology director Theagene Jean-Manasse received a grant of stock options for 20,459 shares on 10/02/2025. The options have an exercise price of $1.8, vest 100% on the grant date, are exercisable immediately, and expire on 10/02/2035. The filing shows the transaction was reported on 10/06/2025 and was filed as a Form 4 by one reporting person. The grant was made under the 2021 Equity Incentive Plan and represents a direct beneficial ownership of 20,459 shares via options.
Cristian Luput, a director of MAIA Biotechnology, Inc. (MAIA), reported a grant of stock options on 10/02/2025. The grant consists of 21,434 options under the company's 2021 Equity Incentive Plan that vest 100% on the grant date and are immediately exercisable. The options have an exercise price of $1.8 per share and expire on 10/02/2035.
The Form 4 was signed on 10/06/2025 and indicates the filing was submitted by one reporting person. The disclosure shows direct beneficial ownership of 21,434 shares following the transaction. No cash proceeds, sales, or other derivative transactions are reported in this filing.